Endocrinology: New guidelines for thyrotoxicosis

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

New evidence-based recommendations from the American Thyroid Association (ATA), published in Thyroid, have been issued to guide clinicians in the management of patients with all forms of thyrotoxicosis (excessively high thyroid hormone activity), including hyperthyroidism.

The guidelines include 124 recommendations on how to evaluate patients and diagnose and manage the different types of disease, how to handle thyrotoxicosis in pregnancy, and how to select and implement the various treatment options such as surgery, radioactivity and antithyroid drugs.

Lead author, Dr Douglas Ross, Massachusetts General Hospital, Boston, MA said some of the highlights of the 2016 guidelines are: "the changing paradigms for the evaluation and management of Graves’ disease with more reliance upon the measurement of thyrotropin receptor antibodies, new approaches for managing hyperthyroid patients desiring pregnancy, new approaches in the management of calcium metabolism prior to thyroid surgery, and a critical re-evaluation of the long-term toxicity of antithyroid drugs." He added that sections on less common causes of thyrotoxicosis have been expanded.

“These ATA guidelines, written by an international and multidisciplinary task force, provide a significant update compared to the previous version published in 2011 because they integrate recent studies and developments in practice trends,” added Dr Peter A. Kopp, Editor-in-Chief of Thyroid.